SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-090982
Filing Date
2024-10-28
Accepted
2024-10-28 08:35:10
Documents
3
Period of Report
2024-10-28

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0218396-6k_neurosense.htm 6-K 10926
2 PRESS RELEASE, DATED OCTOBER 28, 2024, ENTITLED "NEUROSENSE SECURES KEY FDA MEET ea021839601ex99-1_neuro.htm EX-99.1 18718
3 GRAPHIC ex99-1_001.jpg GRAPHIC 14042
  Complete submission text file 0001213900-24-090982.txt   50197
Mailing Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562
Business Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 972-9-9531142
NeuroSense Therapeutics Ltd. (Filer) CIK: 0001875091 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-41084 | Film No.: 241398536
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)